Avella has been selected by Otsuka America Pharmaceutical, Inc. (Otsuka) to distribute Jynarque (tolvaptan), the very first FDA-approved therapy for patients diagnosed with autosomal dominant polycystic kidney disease (ADPKD). Avella is one of just three pharmacies providing access to the medication. ADPKD is one of the most common, life-threatening genetic diseases, diagnosed in 140,000 Americans. In patients with this condition,…